AC Immune, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, closed an equity offering of 14.3 million of its common shares at a price of USD 3.50 per share successfully.
AC Immune expects the gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, to be approximately USD 50.1 million.
The equity offering was led by BVF Partners L.P., with participation from several existing and new institutional investors including Avidity Partners, Redmile Group, and StemPoint Capital LP.
The Company plans to use the proceeds from the offering, together with existing liquidity, primarily to strategically invest in research and clinical development of its current pipeline, its technology platforms, working capital, capital expenditures and general corporate purposes.
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen and Morphomer, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3.
(Press relase / SK)
Please login or sign up to comment.
Commenting guidelines